We need to rewrite as news article with bold and energetic tone, short paragraphs (2-3 sentences max). Use
for headings and
for paragraphs. No heading before lead paragraph. So we need a lead paragraph that hooks. Probably start with a bold statement: FDA approves new drug that doubles survival. Use
maybe for the article title? The rule: “Start directly with the lead paragraph — no heading before it.” So we cannot put
before the lead paragraph. But we need to use
for headings. So we need a heading after the lead? The lead paragraph is the first paragraph, no heading before it. Then we can have an
later for a subheading. But we need to ensure we have an
somewhere. Possibly after the lead, we can put a subheading like
FDA Approves Rasonque
for headings. So we need a heading after the lead? The lead paragraph is the first paragraph, no heading before it. Then we can have an
later for a subheading. But we need to ensure we have an
somewhere. Possibly after the lead, we can put a subheading like
FDA Approves Rasonque
somewhere. Possibly after the lead, we can put a subheading like
FDA Approves Rasonque
. But the lead paragraph must be first, no heading before it. So we start with
… lead …
. Then we can include
for a heading, then more paragraphs.
We must keep under 500 words. Let’s draft.
Lead paragraph: “The FDA has approved a pill that nearly doubles survival for patients with advanced pancreatic cancer, a breakthrough hailed as the biggest advance in decades.” That’s a strong hook. Keep 2-3 sentences max. Maybe 2 sentences.
Paragraphs: each 2-3 sentences. Use bold? The tone: bold and energetic — confident, direct sentences. No hedging. Use strong verbs.
We need to attribute claims to sources. Use quotes from FDA commissioner, specialists. Ensure we attribute.
We need to include side effects list.
We need to keep under 500 words. Let’s count approximate words. We’ll aim ~350.
Structure:
Lead hook.
FDA Approves Rasonque, a New Hope for Pancreatic Cancer
Rasonque (daraxonrasib) is a once‑daily pill that blocks RAS proteins, the drivers of tumor growth in metastatic pancreatic adenocarcinoma. The drug, developed by Revolution Medicines, targets the most common form of the disease.
The FDA cleared Rasonque for adults whose cancer has progressed after prior therapy or who cannot receive combination treatment, granting the approval about six and a half months ahead of the agency’s target date after an expedited review.
“Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard‑to‑treat cancer,” acting FDA Commissioner Kyle Diamantas said in a press release. “Our duty is to deliver more cures and meaningful treatments as quickly as possible,” he added, praising the agency’s scientists.
A trial involving 500 patients showed median overall survival of 13.2 months for those taking Rasonque, versus 6.7 months for standard chemotherapy, effectively doubling survival time.
Patients on the new drug also experienced twice the delay in disease progression and a 60% reduction in death risk compared with chemotherapy recipients.
“It will be transformative in the way we treat pancreas cancer. It’s the biggest development we’ve had in pancreas cancer in decades,” said Andrew Ko, a gastrointestinal cancer specialist at the University of California, speaking to STAT.
Rachna Shroff, a pancreatic cancer specialist at the University of Arizona Cancer Center, recalled an emotional reaction to the results: “Having treated pancreatic cancer for 16 years, I actually started crying in the clinic. This is such an incredibly impactful study for our patients,” she told STAT.
The National Cancer Institute estimates 67,530 Americans will be diagnosed with pancreatic cancer in 2026 and 52,740 will die, with a five‑year survival rate of just 13.3%.
The most common side effects reported with Rasonque include rash, diarrhea, mouth inflammation, nausea, fatigue, vomiting, abdominal pain, swelling, decreased appetite and hemorrhage, according to the FDA.
We need to ensure each paragraph is 2-3 sentences. Let’s check:
Lead paragraph: maybe 2 sentences. “The FDA has approved a pill that nearly doubles survival for patients with advanced pancreatic cancer, a breakthrough hailed as the biggest advance in decades. This approval marks a turning point after years of stagnant outcomes.” That’s 2 sentences.
Next paragraph after heading: maybe 2 sentences. “Rasonque (daraxonrasib) is a once‑daily pill that blocks RAS proteins, the drivers of tumor growth in metastatic pancreatic adenocarcinoma. Developed by Revolution Medicines, it targets the most common form of the disease.” That’s 2 sentences.
Next: “The FDA cleared Rasonque for adults whose cancer has progressed after prior therapy or who cannot receive combination treatment, granting the approval about six and a half months ahead of the agency’s target date after an expedited review.” That’s one sentence, need 2-3. Add another sentence: “The decision reflects a faster than expected timeline for a therapy that addresses an unmet medical need.” That’s 2 sentences.
Next: Quote paragraph. Need 2-3 sentences. ““Today’s approval provides a critical new option for patients facing an extraordinarily difficult and historically hard‑to‑treat cancer,” acting FDA Commissioner Kyle Diamantas said in a press release. “Our duty is to deliver more cures and meaningful treatments as quickly as possible,” he added, praising the agency’s scientists.” That’s 2 sentences.
Next: trial results. 2-3 sentences. “A trial involving 500 patients showed median overall survival of 13.2 months for those taking Rasonque, versus 6.7 months for standard chemotherapy, effectively doubling survival time. Patients also experienced twice the delay in disease progression and a 60% reduction in death risk compared with chemotherapy recipients.” That’s 2 sentences.
Next: specialist quote. 2-3 sentences. ““It will be transformative in the way we treat pancreas cancer. It’s the biggest development we’ve had in pancreas cancer in decades,” said Andrew Ko, a gastrointestinal cancer specialist at the University of California, speaking to STAT.” That’s 2 sentences.
Next: emotional specialist. 2-3 sentences. “Rachna Shroff, a pancreatic cancer specialist at the University of Arizona Cancer Center, recalled an emotional reaction to the results: “Having treated pancreatic cancer for 16 years, I actually started crying in the clinic. This is such an incredibly impactful study for our patients,” she told STAT.” That’s 2 sentences.
Next: statistics. 2-3 sentences. “The National Cancer Institute estimates 67,530 Americans will be diagnosed with pancreatic cancer in 2026 and 52,740 will die, with a five‑year survival rate of just 13.3%.” That’s one sentence; need 2. Add: “These stark numbers underscore the urgent need for more effective therapies.” That’s 2 sentences.
Next: side effects. 2-3 sentences. “The most common side effects reported with Rasonque include rash-